Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.51 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113697 | 0.86 | POLB (0.74) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6893171 | 0.85 | LMNA (1.00) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16027030 | 0.85 | HTR6 (0.66) | ALDH1A1LMNANPSR1HTTKDM4E | |
| SCHEMBL13621791 | 0.85 | ALDH1A1 (0.66) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4361910 | 0.83 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2HTTKDM4E | |
| SCHEMBL13621798 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1518687 | 0.80 | LMNA (0.60) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27794788 | 0.80 | LMNA (0.84) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4354844 | 0.80 | ICMT (0.54) | ALDH1A1LMNASMN1; SMN2POLBCYP19A1 | |
| SCHEMBL4363056 | 0.79 | POLB (0.67) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | claimed |
| US-20220048931-A1 | ANTICANCER INDENES, INDANES, AZAINDENES, AZAINDANES, PHARMACEUTICAL COMPOSITIONS AND USES | ADT PHARMACEUTICALS, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-11186596-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | ADT PHARMACEUTICALS, LLC (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| CN-104230845-B | Semicarbazone derivatives and application thereof | 沈阳药科大学 | 2017-01-25 | — | — | CN | disclosed |
| CN-104230845-A | Semicarbazone derivatives and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-12-24 | — | — | CN | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| EP-1956910-B1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-101360422-B | Oncogenic Ras-specific cytotoxic compound and methods of usethereof | UNIV TEXAS | 2013-10-23 | — | — | CN | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| CN-101360422-A | Oncogenic ras-specific cytotoxic compound and methods of usethereof | UNIV TEXAS (US) | 2009-02-04 | — | — | CN | disclosed |
| EP-1956910-A2 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | The Board of Regents of The University of Texas System (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062399-A2 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048931-A1 | ANTICANCER INDENES, INDANES, AZAINDENES, AZAINDANES, PHARMACEUTICAL COMPOSITIONS AND USES | CDKN1A, CCNA1, CCNA2 | ALDH1A1 28/4885LMNA 1652/4885SMN1; SMN2 1793/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | ALDH1A1 1984/4885LMNA 1586/4885SMN1; SMN2 1774/4885 |
| US-11186596-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | CCNA2, CDKN1A, CCNA1 | ALDH1A1 29/4885LMNA 1868/4885SMN1; SMN2 1953/4885 |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 790/4885LMNA 3617/4885SMN1; SMN2 4170/4885 |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | ALDH1A1 1984/4885LMNA 1586/4885SMN1; SMN2 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.